LUCID CAPITAL MARKETS Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $14
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $14.
LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $14.